Tradestie Institutional Equity Comparison Engine

REVB vs KAVL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

REVB Overall Edge

REVB Captures Institutional Edge (3โ€“0 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Revelation Biosciences, Inc. Common Stock (REVB) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, REVB trades at 0.9x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus KAVL at N/M Forward P/E and -392.1% operating margin (-80.0% YoY). In options structure, REVB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against KAVL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner REVB
REVB 0.9x vs KAVL N/M Fwd P/E
Growth & Margin Winner REVB
Op Margin 0.0% vs -392.1% ยท YoY +0.0% vs -80.0%
Momentum & Technical Winner REVB
1Y +309.9% vs -83.9% ยท 52W Pos 71% vs 1%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
REVB NASDAQ
Revelation Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$3.50
-5.15% 1D
Market Cap $2.1M
1M Return -4.89%
1Y Return +309.93%
Forward P/E 0.9x
Unified AI Score
44.6 / 100 HOLD
Tech 20.0 Fund 37.0 Flow 50.0 Mom 36.0
KAVL NASDAQ
Kaival Brands Innovations Group, Inc
Retail-Nonstore Retailers
$0.14
-12.96% 1D
Market Cap $1.8M
1M Return -71.05%
1Y Return -83.86%
Forward P/E N/M
Unified AI Score
49.1 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 63.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: REVB +309.93% KAVL -83.86% Spread: +71.84 pp (REVB Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
REVB TTM Op. Margin: 0.0% KAVL TTM Op. Margin: -392.1%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on REVB vs KAVL. Trailing 12-month operating profitability (REVB 0.0% vs KAVL -392.1%) and valuation multiples (REVB 0.9x vs KAVL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: REVB (6) vs KAVL (2)
Institutional Metric REVB KAVL Criterion Row Winner
Market Capitalization Scale $2.1M $1.8M Larger Scale Tie
Trailing P/E Ratio Valuation 0.9x N/M Lower Multiple REVB
Forward P/E Ratio Valuation 0.9x N/M Lower Multiple REVB
Revenue Growth (YoY) Growth +0.0% -80.0% Higher Growth REVB
Operating Margin (TTM) Profitability 0.0% -392.1% Higher Margin REVB
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -133.4% -68.6% Higher ROE KAVL
52-Week Range Position Momentum 71% ($0โ€“$5) 1% ($0โ€“$2) Stronger Trend REVB
Beta / 30D Volatility Risk Regime 2.88ฮฒ ยท 101% Vol 0.88ฮฒ ยท 244% Vol Lower Realized Risk REVB
Unified Institutional Score Composite Signal 44.6 / 100 (HOLD) 49.1 / 100 (HOLD) Higher Composite KAVL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full REVB vs KAVL Buy Guide
REVB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live REVB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
KAVL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live KAVL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither REVB nor KAVL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.